Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
'Remarkable' AI tool designs mRNA vaccines that are more potent and stable.
Dolgin, Elie.
Nature ; 2023 May 02.
Article in English | MEDLINE | ID: covidwho-2321013
2.
Trial settles debate over best design for mRNA in COVID vaccines.
Dolgin, Elie.
Nature ; 613(7944): 419-420, 2023 01.
Article in English | MEDLINE | ID: covidwho-2185711

Subject(s)
COVID-19 Vaccines , COVID-19 , Clinical Trials as Topic , Drug Design , RNA, Messenger , Vaccine Development , mRNA Vaccines , Humans , COVID-19/prevention & control , COVID-19 Vaccines/chemistry , COVID-19 Vaccines/genetics , RNA, Messenger/chemistry , RNA, Messenger/genetics , mRNA Vaccines/chemistry , mRNA Vaccines/genetics , Vaccine Development/standards , Drug Design/standards
3.
Better lipids to power next generation of mRNA vaccines.
Dolgin, Elie.
Science ; 376(6594): 680-681, 2022 05 13.
Article in English | MEDLINE | ID: covidwho-2103175

ABSTRACT

New delivery systems aim to increase vaccine potency and reduce side effects.


Subject(s)
Lipids , Nanoparticles , mRNA Vaccines , Humans , Lipids/chemistry , Nanoparticles/adverse effects , Nanoparticles/chemistry , mRNA Vaccines/administration & dosage , mRNA Vaccines/chemistry
4.
Pan-coronavirus vaccine pipeline takes form.
Dolgin, Elie.
Nat Rev Drug Discov ; 21(5): 324-326, 2022 05.
Article in English | MEDLINE | ID: covidwho-1805574

Subject(s)
COVID-19 Vaccines , Coronavirus , Humans , Vaccination
5.
Omicron thwarts some of the world's most-used COVID vaccines.
Dolgin, Elie.
Nature ; 601(7893): 311, 2022 01.
Article in English | MEDLINE | ID: covidwho-1625143

Subject(s)
COVID-19 , Vaccines , COVID-19 Vaccines , Humans , SARS-CoV-2
6.
T-cell vaccines could top up immunity to COVID, as variants loom large.
Dolgin, Elie.
Nat Biotechnol ; 40(1): 3-4, 2022 01.
Article in English | MEDLINE | ID: covidwho-1569232

Subject(s)
COVID-19 , Vaccines , COVID-19/prevention & control , COVID-19 Vaccines/therapeutic use , Humans , SARS-CoV-2/genetics , T-Lymphocytes
7.
Omicron is supercharging the COVID vaccine booster debate.
Dolgin, Elie.
Nature ; 2021 Dec 02.
Article in English | MEDLINE | ID: covidwho-1550270
8.
How protein-based COVID vaccines could change the pandemic.
Dolgin, Elie.
Nature ; 599(7885): 359-360, 2021 11.
Article in English | MEDLINE | ID: covidwho-1505887

Subject(s)
COVID-19 Vaccines , COVID-19/epidemiology , COVID-19/prevention & control , Vaccines, Subunit , COVID-19/immunology , COVID-19 Vaccines/adverse effects , COVID-19 Vaccines/biosynthesis , COVID-19 Vaccines/immunology , COVID-19 Vaccines/standards , Female , Humans , Pandemics/prevention & control , Time Factors , Vaccination Hesitancy/psychology , Vaccines, Subunit/adverse effects , Vaccines, Subunit/biosynthesis , Vaccines, Subunit/immunology , Vaccines, Subunit/standards
9.
mRNA flu shots move into trials.
Dolgin, Elie.
Nat Rev Drug Discov ; 20(11): 801-803, 2021 11.
Article in English | MEDLINE | ID: covidwho-1493036

Subject(s)
Clinical Trials as Topic , Influenza Vaccines , Vaccines, Synthetic , COVID-19 Vaccines , Humans , Influenza Vaccines/adverse effects , Influenza Vaccines/chemistry , Influenza Vaccines/genetics , Influenza Vaccines/immunology , RNA, Messenger , Vaccine Efficacy , Vaccines, Synthetic/adverse effects , Vaccines, Synthetic/chemistry , Vaccines, Synthetic/immunology
10.
COVID vaccine immunity is waning - how much does that matter?
Dolgin, Elie.
Nature ; 597(7878): 606-607, 2021 09.
Article in English | MEDLINE | ID: covidwho-1434083

Subject(s)
COVID-19 Vaccines/immunology , COVID-19/immunology , COVID-19/prevention & control , Immunity, Cellular/immunology , Immunity, Humoral/immunology , B-Lymphocytes/immunology , COVID-19/epidemiology , COVID-19/virology , Evolution, Molecular , Germinal Center/cytology , Germinal Center/immunology , Humans , Israel/epidemiology , Qatar/epidemiology , SARS-CoV-2/genetics , SARS-CoV-2/pathogenicity , T-Lymphocytes/immunology , Time Factors , United Kingdom/epidemiology
11.
The tangled history of mRNA vaccines.
Dolgin, Elie.
Nature ; 597(7876): 318-324, 2021 09.
Article in English | MEDLINE | ID: covidwho-1408162

Subject(s)
COVID-19 Vaccines , Drug Industry/history , Research Personnel/history , Research/history , Vaccines, Synthetic/history , Animals , Clinical Trials as Topic , Drug Industry/economics , Genetic Therapy/history , History, 20th Century , History, 21st Century , Humans , Liposomes , Mice , Nanoparticles/chemistry , Neoplasms/genetics , Neoplasms/immunology , Neoplasms/therapy , Nobel Prize , Patents as Topic/history , Pseudouridine/metabolism , RNA/biosynthesis , RNA/genetics , RNA Stability , Rabbits , Spike Glycoprotein, Coronavirus/chemistry , Spike Glycoprotein, Coronavirus/immunology , Toll-Like Receptors/immunology , Vaccines, DNA/history , Vaccines, Synthetic/adverse effects , Vaccines, Synthetic/therapeutic use
12.
Core Concept: The pandemic is prompting widespread use-and misuse-of real-world data.
Dolgin, Elie.
Proc Natl Acad Sci U S A ; 117(45): 27754-27758, 2020 11 10.
Article in English | MEDLINE | ID: covidwho-1383161

Subject(s)
Databases, Factual/trends , Pragmatic Clinical Trials as Topic/methods , Pragmatic Clinical Trials as Topic/statistics & numerical data , COVID-19/epidemiology , Humans , Influenza, Human/epidemiology , Pandemics , SARS-CoV-2/pathogenicity , Scientific Misconduct/trends
13.
Publisher Correction: 'Super-antibodies' could curb COVID-19 and help avert future pandemics.
Dolgin, Elie.
Nat Biotechnol ; 39(7): 893, 2021 Jul.
Article in English | MEDLINE | ID: covidwho-1303779
14.
Quarter-dose of Moderna COVID vaccine still rouses a big immune response.
Dolgin, Elie.
Nature ; 2021 Jul 09.
Article in English | MEDLINE | ID: covidwho-1303756
15.
Is one vaccine dose enough if you've had COVID? What the science says.
Dolgin, Elie.
Nature ; 595(7866): 161-162, 2021 07.
Article in English | MEDLINE | ID: covidwho-1303747

Subject(s)
COVID-19 , Vaccines , Humans , SARS-CoV-2
16.
CureVac COVID vaccine let-down spotlights mRNA design challenges.
Dolgin, Elie.
Nature ; 594(7864): 483, 2021 06.
Article in English | MEDLINE | ID: covidwho-1286424

Subject(s)
Antibodies, Neutralizing/analysis , Antibodies, Neutralizing/immunology , COVID-19 Vaccines/chemistry , COVID-19 Vaccines/immunology , Vaccines, Synthetic/chemistry , Vaccines, Synthetic/immunology , 2019-nCoV Vaccine mRNA-1273 , Animals , BNT162 Vaccine , COVID-19 Vaccines/administration & dosage , COVID-19 Vaccines/adverse effects , Clinical Trials, Phase I as Topic , Cold Temperature , Drug Storage , Germany , Haplorhini , Humans , Pseudouridine/genetics , Pseudouridine/immunology , Pseudouridine/metabolism , RNA Stability , Rats , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/adverse effects
17.
'Super-antibodies' could curb COVID-19 and help avert future pandemics.
Dolgin, Elie.
Nat Biotechnol ; 39(7): 783-785, 2021 07.
Article in English | MEDLINE | ID: covidwho-1279885
18.
Coronapod: CureVac disappoints in COVID vaccine trial.
Baker, Noah; Dolgin, Elie.
Nature ; 2021 Jun 18.
Article in English | MEDLINE | ID: covidwho-1275897
19.
The race for antiviral drugs to beat COVID - and the next pandemic.
Dolgin, Elie.
Nature ; 592(7854): 340-343, 2021 04.
Article in English | MEDLINE | ID: covidwho-1192481

Subject(s)
Antiviral Agents/therapeutic use , COVID-19 Drug Treatment , Drug Development/trends , Pandemics , Adenosine Monophosphate/administration & dosage , Adenosine Monophosphate/analogs & derivatives , Adenosine Monophosphate/therapeutic use , Alanine/administration & dosage , Alanine/analogs & derivatives , Alanine/therapeutic use , Animals , Antiviral Agents/pharmacology , Birds/virology , COVID-19/virology , Clinical Trials as Topic , Coronavirus/classification , Coronavirus/drug effects , Coronavirus Infections/epidemiology , Cytidine/administration & dosage , Cytidine/analogs & derivatives , Cytidine/chemical synthesis , Cytidine/therapeutic use , Drug Industry/trends , Europe , Humans , Hydroxylamines/administration & dosage , Hydroxylamines/chemical synthesis , Hydroxylamines/therapeutic use , Indoles/administration & dosage , Indoles/therapeutic use , Influenza, Human/drug therapy , Influenza, Human/virology , Leucine/administration & dosage , Leucine/therapeutic use , Orthomyxoviridae/drug effects , Pyrrolidinones/administration & dosage , Pyrrolidinones/therapeutic use , Severe Acute Respiratory Syndrome/drug therapy , Severe Acute Respiratory Syndrome/epidemiology , Strategic Stockpile , United States
20.
Vaccine Technologies Jockey for Primacy in Pandemic Response.
Dolgin, Elie.
Mol Ther ; 29(3): 901-903, 2021 03 03.
Article in English | MEDLINE | ID: covidwho-1077414

Subject(s)
Pandemics/prevention & control , Vaccines/therapeutic use , Humans
SEND TO:
Email
Export
Print
RSS
XML
SELECTION OF CITATIONS
SEARCH DETAIL